Revive Therapeutics : RVV Deck October 2021

A SPECIALTY LIFE

SCIENCES COMPANY

Corporate Presentation

OCTOBER 2021

US: FRANKFURT:

RVVTF 31R

Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [e-mail]

FORWARD LOOKING STATEMENTS

Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.

2

REVIVE THERAPEUTICS

Specialty life sciences company	FDA approved Phase 3 clinical	Developing novel Psilocybin
focused on repurposing drugs	trial for Bucillamine in the	and Cannabidiol therapeutics
for rare disorders and	treatment of COVID-19	for various CNS and
infectious diseases		inflammatory disorders

Robust patent portfolio	Near-team value creation
covering methods and	milestones
compositions of drugs

Bucillamine

Psilocybin

Cannabidiol

© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.

3

PHARMACEUTICAL STRATEGY

Clinical development of		Targeting Rare		Novel Uses,		Targeting FDA
Psilocybin, Cannabidiol		Disorders and		Formulations, and		Designations:
and Bucillamine		Infectious Diseases,		Delivery System		Orphan, Fast track,
		Neurological Disorders,				Breakthrough
		Mental Health and				therapy
		Liver Diseases

© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.

4

PATENT PORTFOLIO

Title	USPTO No.	Status
Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19	62/991,996	Provisional patent filed
Use of Bucillamine in the Treatment of Gout	US9662305	Issued on May 30, 2017
Drug Delivery System	US 8642088	Issued on February 4, 2014
US 9545423	Issued on January 17, 2017
	US 10104888	Issued on October 23, 2018
Psilocybin effervescent and psilocybin tablet - Solid Oral Pharmaceutical Compositions	62/985,052	Provisional patent filed
Psilocybin hard-shell capsules - Pharmaceutical Capsule Compositions	62/985,070	Provisional patent filed
Psilocybin gum drops - Pharmaceutical Gumdrop Compositions	62/985,084	Provisional patent filed
Psilocybin oral strips and transmucosal - Thin-Film Pharmaceutical Delivery System and Formulations	62/985,098	Provisional patent filed
Psilocybin - Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration	62/984,590	Provisional patent filed
Methods for the Extraction and Crystallization of Psilocybin	62/985,360	Provisional patent filed
Psilocybin in the Treatment of Neurological Brain Injury	63/011,493	Provisional patent filed
Use of Psilocybin in the Treatment of Cancer	63/133,913	Provisional patent filed
Psilocybin Pharmaceutical Combination Therapies	63/125,106	Provisional patent filed
Use of Cannabidiol in the Treatment of Autoimmune Hepatitis	US 8242178	Issued on August 14, 2012

© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.

5